
- /
- Supported exchanges
- / US
- / CRSP.NASDAQ
Crispr Therapeutics AG (CRSP NASDAQ) stock market data APIs
Crispr Therapeutics AG Financial Data Overview
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a revolutionary technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting glypican-3 (GPC3) for the potential treatment of solid tumors. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease (SCD), and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting cluster of differentiation 19 (CD19) and CTX131 targeting CD70 for oncology and autoimmune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and CTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated, Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Crispr Therapeutics AG data using free add-ons & libraries
Get Crispr Therapeutics AG Fundamental Data
Crispr Therapeutics AG Fundamental data includes:
- Net Revenue: 37 675 K
- EBITDA: -455 240 992
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-30
- EPS/Forecast: -1.2768
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Crispr Therapeutics AG News

Biotech Stock for Options Bears to Target Right Now
Biotech stock Crispr Therapeutics Inc's (NASDAQ:CRSP) June rally appears to be coming to an end. The shares are looking to snap a seven-day win streak, down 0.6% at $42.69 at last glance. Plus, after ...


CRISPR Therapeutics Gains 14% in a Month: How to Play the Stock?
Shares of CRISPR Therapeutics CRSP have risen 14% over the past month, likely driven by encouraging results from the first candidates in its in vivo pipeline. CRSP’s Positive In Vivo Therapy Data ...

CRISPR Therapeutics AG (CRSP) Rises Higher Than Market: Key Facts
The latest trading session saw CRISPR Therapeutics AG (CRSP) ending at $42.94, denoting a +2.02% adjustment from its last day's close. The stock outperformed the S&P 500, which registered a daily gain...

Crispr extends gains for the seventh consecutive trading day
[CRISPR research in laboratory] Bill Oxford/iStock via Getty Images Biopharmaceutical company Crispr Therapeutics (NASDAQ:CRSP [https://seekingalpha.com/symbol/CRSP]) extended gains for the seventh s...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.